BNGONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Bionano Genomics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.22−0.03 (-2.40%)
Close on Oct 19, 2026
- Market cap
- $14.09M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.68 (−35.79%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Bionano Genomics, Inc. grew revenue 10.0% to $30.18M over the twelve months to Jun 30, 2026.
Revenue
$30.18M
+10.0% vs. a year earlier
Operating income
-$32.19M
TTM Q2 2026
EPS, diluted
-$3.76
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $14.09M
- P/E ratio
- –
- Price to sales
- 0.47
- Price to book
- 0.45
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $30.18M
- Net income
- -$32.16M
- EPS, diluted
- -$3.76
- Book value per share
- $2.74
- Diluted shares
- 12M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$30.18M+10.0% YoY
Gross profit
$14.34M+934.3% YoY
Operating income
-$32.19M
Net income
-$32.16M
EPS, diluted
-$3.76
Free cash flow
–
Reported periodTrailing twelve months